News Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
28.16 ^USD	+0.97%		-0.21%	+0.25%

Apr. 09	Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	MT
Mar. 05	Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	Apr. 17	MT
Royalty Pharma Declares Second Quarter 2024 Dividend	Apr. 17	GL
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	Apr. 17	CI
Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	Apr. 09	MT
Royalty Pharma : EEO-1 2023 Consolidated Report	Apr. 02	PU
Royalty Pharma : TD Cowen Health Care Conference Transcript	Mar. 07	PU
Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	Mar. 05
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference	Feb. 28	GL
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference	Feb. 28	AQ
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	Feb. 20	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	Feb. 20	MT
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	Feb. 15	CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases	Feb. 15	MT
Royalty Pharma: Q4 Earnings Snapshot	Feb. 15	AQ
Transcript : Royalty Pharma plc, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M	Feb. 15	MT
Royalty Pharma Reports Q4 and Full Year 2023 Results	Feb. 15	GL
Royalty Pharma Reports Q4 and Full Year 2023 Results	Feb. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Summary

Filters